• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.
J Am Acad Dermatol. 2022 Jan;86(1):232-234. doi: 10.1016/j.jaad.2021.01.096. Epub 2021 Feb 2.
2
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.EMA 审查柔红霉素和阿糖胞苷包封在脂质体中（Vyxeos，CPX-351）用于治疗新诊断的成人、治疗相关的急性髓系白血病或伴骨髓增生异常相关改变的急性髓系白血病。
Oncologist. 2020 Sep;25(9):e1414-e1420. doi: 10.1634/theoncologist.2019-0785. Epub 2020 Apr 13.
3
Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.脂质体阿糖胞苷-柔红霉素（CPX-351）外渗：病例报告与文献综述
Anticancer Res. 2018 Dec;38(12):6927-6930. doi: 10.21873/anticanres.13070.
4
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.对三种急性髓系白血病诱导化疗方案的回顾性分析，包括CPX-351、含或不含克拉屈滨的阿糖胞苷/柔红霉素。
Leuk Lymphoma. 2022 Nov;63(11):2645-2651. doi: 10.1080/10428194.2022.2092855. Epub 2022 Jul 5.
5
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.多中心比较大剂量阿糖胞苷方案与脂质体柔红霉素联合阿糖胞苷（CPX-351）治疗继发性急性髓细胞白血病患者的疗效。
Leuk Lymphoma. 2021 Sep;62(9):2184-2192. doi: 10.1080/10428194.2021.1907378. Epub 2021 Apr 8.
6
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.CPX-351 与阿糖胞苷/柔红霉素治疗高危/继发性急性髓系白血病老年患者的巩固治疗结果。
Leuk Lymphoma. 2020 Mar;61(3):631-640. doi: 10.1080/10428194.2019.1688320. Epub 2019 Nov 25.
7
Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.柔红霉素脂质体与阿糖胞苷（Vyxeos®）治疗伴骨髓增生异常相关变化的急性髓细胞白血病后，反复出现且可逆的双侧手掌蓝色变色。
J Oncol Pharm Pract. 2021 Sep;27(6):1539-1541. doi: 10.1177/1078155220978452. Epub 2020 Dec 13.
8
Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.脂质体柔红霉素-阿糖胞苷（CPX-351）在治疗新诊断的继发性急性髓细胞白血病中的应用：老药新用。
Best Pract Res Clin Haematol. 2019 Jun;32(2):127-133. doi: 10.1016/j.beha.2019.05.005. Epub 2019 May 13.
9
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.FDA 批准概要：（柔红霉素和阿糖胞苷）脂质体注射剂用于治疗高危急性髓系白血病的成人患者。
Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12.
10
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
Lancet Haematol. 2023 Jul;10(7):e481-e482. doi: 10.1016/S2352-3026(23)00153-9. Epub 2023 May 25.

引用本文的文献

1
Saikosaponin A Mediates the Anti-Acute Myeloid Leukemia Effect via the P-JNK Signaling Pathway Induced by Endoplasmic Reticulum Stress.柴胡皂苷A通过内质网应激诱导的P-JNK信号通路介导抗急性髓系白血病作用。
Drug Des Devel Ther. 2025 Mar 17;19:1983-2001. doi: 10.2147/DDDT.S498458. eCollection 2025.
2
Dermatologic complications in transplantation and cellular therapy for acute leukemia.急性白血病移植和细胞治疗的皮肤并发症。
Best Pract Res Clin Haematol. 2023 Jun;36(2):101464. doi: 10.1016/j.beha.2023.101464. Epub 2023 Apr 6.

本文引用的文献

1
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.CPX-351（阿糖胞苷和柔红霉素）脂质体注射液与常规阿糖胞苷联合柔红霉素治疗新诊断的老年继发性急性髓系白血病患者的比较。
J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.
2
Generalized benign cutaneous reaction to cytarabine.阿糖胞苷致泛发性良性皮肤反应。
J Am Acad Dermatol. 2015 Nov;73(5):821-8. doi: 10.1016/j.jaad.2015.07.010. Epub 2015 Aug 29.
3
Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.癌症的化疗药物和靶向治疗的皮肤反应：第一部分。常规化疗药物。
J Am Acad Dermatol. 2014 Aug;71(2):203.e1-203.e12; quiz 215-6. doi: 10.1016/j.jaad.2014.04.014.
4
High-dose cytosine arabinoside-induced cutaneous reactions.大剂量阿糖胞苷引起的皮肤反应。
J Eur Acad Dermatol Venereol. 2002 Sep;16(5):481-5. doi: 10.1046/j.1468-3083.2002.00395.x.
5
Cytarabine-induced palmar-plantar erythema.
Arch Dermatol. 1985 Oct;121(10):1240-1.

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.

作者信息

Stoll Joseph R, Battle Laura, Moy Andrea, Dusza Stephen W, Park Jae H, Tallman Martin S, Taylor Justin, Markova Alina

机构信息

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

J Am Acad Dermatol. 2022 Jan;86(1):232-234. doi: 10.1016/j.jaad.2021.01.096. Epub 2021 Feb 2.

DOI:10.1016/j.jaad.2021.01.096
PMID:33539850
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9398188/
Abstract
摘要